CoChat
Cited by 177

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design: Figure 1

Open access
Mahfoud, Felix, Böhm, Michael, Azizi, Michel, Pathak, Atul, Durand Zaleski, Isabelle, Ewen, Sebastian, Tsioufis, Kostantinos, Andersson, Bert, Blankestijn, Peter J., Burnier, Michel, Chatellier, Gilles, Gafoor, Sameer, Grassi, Guido, Joner, Michael, Kjeldsen, Sverre E., Lüscher, Thomas Felix, Lobo, Melvin D., Lotan, Chaim, Parati, Gianfranco, Redon, Josep, Ruilope, Luis, Sudano, Isabella, Ukena, Christian, van Leeuwen, Evert, Volpe, Massimo, Windecker, Stephan, Witkowski, Adam, Wijns, William, Zeller, Thomas, Schmieder, Roland E. · 2015 · European Heart Journal

Abstract

Approximately 8–18% of all patients with high blood pressure (BP) are apparently resistant to drug treatment.1,2 In this situation, new strategies to help reduce BP are urgently needed but the complex pathophysiology of resistant hypertension makes this search difficult. Not surprisingly in this context, the latest non-drug treatment which triggered controversy is catheter-based renal denervation (RDN).3,4 The method uses radiofrequency energy, or alternatively ultrasound or chemical denervation, to disrupt renal nerves within the renal artery wall, thereby reducing sympathetic efferent and sensory afferent signalling to and from the kidneys.5,6 Various experimental models of hypertension strongly support this concept7,8 and available evidence also suggests that sympathetic nervous system activation contributes to the development and progression of hypertension and subsequently to target organ damage.7–11 Historical observations have shown that surgical sympathectomy can reduce BP as well as morbidity and mortality in patients with uncontrolled hypertension.12,13 However, the clinical evidence in support of RDN as an effective interventional technique in patients with resistant hypertension is conflicting. A number of observational studies and three randomized, controlled trials (Symplicity HTN-2, Prague-15, and DENERHTN) support both safety and efficacy of this new therapy14–22 but some smaller studies and the large, single-blind, randomized, sham-controlled symplicity HTN-3 trial failed to show superiority of RDN when compared with medical therapy alone.23–25 Whatever the shortcomings of individual trials may be, the possibility remains that the observed BP responses were due to placebo response, the Hawthorne effect, regression to the mean, unknown co-interventions or other bias.26 The design, conduct, and interpretation of the trials in RDN have been discussed extensively elsewhere.27–30 Accordingly, since the publication of the Symplicity HTN-3 results, some health care providers have been unwilling to endorse RDN in the absence of incontrovertible efficacy data. However, current evidence also seems equally insufficient to declare the technology a proven failure. Whenever doubts arise around the effectiveness of new treatment approaches, an assessment by rigorously designed studies is necessary to furnish conclusive evidence. With this controversy in mind, a multidisciplinary European Expert Group has convened on 9 December 2014 to assess the current gaps in our knowledge about RDN, unmet needs and where clinical trials may best be focused in the future. The current document represents a summary of the main conclusions of this clinical consensus conference. The topics are divided into three sections: procedural aspects, patient populations, and design considerations for future clinical trials. In the years, since the first studies on RDN, our view of the technique has significantly evolved.31–34 Far from being a simple procedure that could be performed with little training by any interventionist regardless of their subspecialty, it is now recognized as a complex, specialized therapy whose primary and secondary success depends on a large number of influencing factors and uncertainties that may not be filled by our current knowledge. Moreover, there are a number of different systems, methods, and strategies currently employed in RDN (using uni- or bipolar radiofrequency energy, high-energy ultrasound and chemical ablation), which make it difficult to standardize treatment recommendations and compare different treatment modalities in patients. The European Expert Group agreed that several procedural aspects need to be considered for future clinical trials, as they would help to improve reliability and thereby efficacy of the denervation technique: Preclinical studies to assess the safety and efficacy of any RDN system are currently performed in healthy, normotensive animals. Our knowledge of peri-arterial renal nerve distribution in chronically hypertensive patients is very limited and it is unclear how far preclinical results can be applied to vessels subject to atherosclerosis. A suitable, hypertensive animal model would greatly help to answer open questions and to compare the different available catheters in terms of both surrogate markers (e.g. histological renal nerve ablation, renal norepinephrine content) and BP effects. The optimal degree of contact against the renal artery wall and the depth, location, duration, and intensity of energy delivery to provide the best procedural results are still being investigated. An extensive human autopsy study has shown the large variation in distribution and density of the renal sympathetic nervous system in the adventitia of renal arteries (Figure 1)33: the highest average number of nerves was observed in the proximal and middle segments of the renal artery and the lowest in the distal segments. Additionally, the mean distance from the lumen to the nerve was m

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehv192

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 177

Metadata

Authors
Mahfoud, F., Böhm, M., Azizi, M., Pathak, A., Durand Zaleski, I., Ewen, S., Tsioufis, K., Andersson, B., Blankestijn, P. J., Burnier, M., Chatellier, G., Gafoor, S., Grassi, G., Joner, M., Kjeldsen, S. E., Lüscher, T. F., Lobo, M. D., Lotan, C., Parati, G., Redon, J., Ruilope, L., Sudano, I., Ukena, C., van Leeuwen, E., Volpe, M., Windecker, S., Witkowski, A., Wijns, W., Zeller, T., & Schmieder, R. E.
Venue
European Heart Journal
Published
2015-05-18
Volume
36
Issue
33
Pages
2219-2227
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2150305971
Cited by
177
References
15
FWCI
23.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design: Figure 1. https://app.cochat.ai/papers/10.1093/eurheartj/ehv192
The paper
Mahfoud, F., Böhm, M., Azizi, M., Pathak, A., Durand Zaleski, I., Ewen, S., Tsioufis, K., Andersson, B., Blankestijn, P. J., Burnier, M., Chatellier, G., Gafoor, S., Grassi, G., Joner, M., Kjeldsen, S. E., Lüscher, T. F., Lobo, M. D., Lotan, C., Parati, G., . . . Schmieder, R. E. (2015). Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design: Figure 1. European Heart Journal. https://doi.org/10.1093/eurheartj/ehv192

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.